73090-70-7|Epiroprim|5-(3,5-diethoxy-4-(1H-pyrrol-1-yl)benzyl)pyrimidine-2,4-diamine|-范德生物科技公司

Epiroprim

NMR下载 COA and HPLC MSDS下载
names：
5-(3,5-diethoxy-4-(1H-pyrrol-1-yl)benzyl)pyrimidine-2,4-diamine
CAS号：
73090-70-7
MDL Number：
MF(分子式)： C19H23N5O2 MW(分子量)： 353.42
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Epiroprim
英文别名	Epiroprim; Epiroprime; Ro 11-8958; Ro-11-8958; Ro11-8958;
CAS号	73090-70-7
Inchi	InChI=1S/C19H23N5O2/c1-3-25-15-10-13(9-14-12-22-19(21)23-18(14)20)11-16(26-4-2)17(15)24-7-5-6-8-24/h5-8,10-12H,3-4,9H2,1-2H3,(H4,20,21,22,23)
InchiKey	NMARPFMJVCXSAV-UHFFFAOYSA-N
分子式 Formula	C19H23N5O2
分子量 Molecular Weight	353.42
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Epiroprim(CAS:73090-70-7):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Epiroprim is an analog of trimethoprim and an inhibitor of dihydrofolate reductase.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Martinez A, Allegra CJ, Kovacs JA. Efficacy of epiroprim (Ro11-8958), a new dihydrofolate reductase inhibitor, in the treatment of acute Toxoplasma infection in mice. Am J Trop Med Hyg. 1996 Mar;54(3):249-52. PubMed PMID: 8600759.

[2]Dhople AM. In vitro activity of epiroprim, a dihydrofolate reductase inhibitor, singly and in combination with brodimoprim and dapsone, against Mycobacterium leprae. Int J Antimicrob Agents. 1999 Aug;12(4):319-23. PubMed PMID: 10493608.

[3] Chang HR, Arsenijevic D, Comte R, Polak A, Then RL, Pechère JC. Activity of epiroprim (Ro 11-8958), a dihydrofolate reductase inhibitor, alone and in combination with dapsone against Toxoplasma gondii. Antimicrob Agents Chemother. 1994 Aug;38(8):1803-7. PubMed PMID: 7986011; PubMed Central PMCID: PMC284639.

[4] Luttringer O, Theil FP, Poulin P, Schmitt-Hoffmann AH, Guentert TW, Lavé T. Physiologically based pharmacokinetic (PBPK) modeling of disposition of epiroprim in humans. J Pharm Sci. 2003 Oct;92(10):1990-2007. PubMed PMID: 14502539.

[5] Locher HH, Schlunegger H, Hartman PG, Angehrn P, Then RL. Antibacterial activities of epiroprim, a new dihydrofolate reductase inhibitor, alone and in combination with dapsone. Antimicrob Agents Chemother. 1996 Jun;40(6):1376-81. PubMed PMID: 8726004; PubMed Central PMCID: PMC163334.

6: Lee HS, Chang HR, Khoo YM. Simple HPLC determination of the concentrations of epiroprim in the serum and brains of mice. J Pharm Pharmacol. 1996 Oct;48(10):1090-2. PubMed PMID: 8953514.7: N'guessan K, Dosso M, Marchal G, Chavarot P, Romain F, Pescher P, Edy. [Preliminary study on isoniazid-epiroprim combination in a tuberculosis murine model]. Bull Soc Pathol Exot. 2002 Nov;95(4):265-8. French. PubMed PMID: 12596375.8: Dosso M, Ouattara L, Cherif AM, Bouzid SA, Haller L, Fernex M. Experimental in vitro efficacy study on the interaction of epiroprim plus isoniazid against Mycobacterium tuberculosis. Chemotherapy. 2001 Mar-Apr;47(2):123-7. PubMed PMID: 11173814.9: Mehlhorn H, Dankert W, Hartman PG, Then RL. A pilot study on the efficacy of epiroprim against developmental stages of Toxoplasma gondii and Pneumocystis carinii in animal models. Parasitol Res. 1995;81(4):296-301. PubMed PMID: 7624286.10: Brun-Pascaud M, Chau F, Garry L, Jacobus D, Derouin F, Girard PM. Combination of PS-15, epiroprim, or pyrimethamine with dapsone in prophylaxis of Toxoplasma gondii and Pneumocystis carinii dual infection in a rat model. Antimicrob Agents Chemother. 1996 Sep;40(9):2067-70. PubMed PMID: 8878582; PubMed Central PMCID: PMC163474.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开